CDXC

ChromaDex Corporation

1.42 USD

Last updated Dec 11, 23:00 UTC

Yesterday HIGH

$1.41

Yesterday LOW

$1.33

52w HIGH

$2.24

52w LOW

$1.25

EPS

-0.01

PE

-142.00

Next Earnings

Mar 6, 2024

Overview News Insider Transactions Government Trades

ChromaDex Corporation stock is up 3.65% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 7 December’s closed higher than November.

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. It researches on nicotinamide adenine dinucleotide (NAD+) and develops and commercializes proprietary-based ingredient technologies. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Irvine, United States Of America

Website

chromadex.com

richadhand@benzinga.com

Mon Mar 13, 2023

HC Wainwright & Co. Maintains Buy on ChromaDex, Lowers Price Target to $5

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:CDXC) with a Buy and lowers the price target from $5.5 to $5.
Benzinga Insights

Fri Mar 10, 2023

ChromaDex Earnings Perspective: Return On Capital Employed
mahesh@benzinga.com

Wed Mar 8, 2023

ChromaDex Q4 EPS $(0.02), Inline, Sales $21.00M Miss $21.14M Estimate

ChromaDex (NASDAQ:CDXC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 75 percent increase over losses of $(0.08) per share from the same period last year. The company
Benzinga Insights

Wed Mar 8, 2023

Earnings Scheduled For March 8, 2023

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.
Benzinga Insights

Tue Mar 7, 2023

Earnings Preview: ChromaDex
Happy Mohamed

Wed Feb 22, 2023

ChromaDex Announces Issuance Of New U.S. Patent On Dihydronicotinamide Riboside And Dihydronicotinic Acid Riboside

Preclinical research suggests that NRH may be among the most potent and efficient of NAD+ precursors, and shows promise as a new therapeutic approach to ameliorating age-related NAD+ decline ChromaDex Corp.
Benzinga Newsdesk

Tue Feb 21, 2023

ChromaDex Updates On Intellectual Property Portfolio; Says Business Is Not Impacted By Recent Court Decision Related To One Of The Dartmouth Patents Slated To Expire In 2026

Last week, the U.S. Court of Appeals for the Federal Circuit affirmed a prior invalidity decision regarding the 807 Dartmouth patent.
Benzinga Newsdesk

Wed Feb 1, 2023

HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $5.5 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:CDXC) with a Buy and maintains $5.5 price target.
Happy Mohamed

Tue Jan 31, 2023

ChromaDex Shares Promising Findings From A Clinical Study Showcasing Combined Metabolic Activators, Featuring Nicotinamide Riboside, Improved Cognitive Functions In Alzheimer's Disease Patients

This first-of-its-kind human clinical study in AD patients showcased CMA supplementation significantly improved cognitive function and associated biomarkers ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company
Benzinga Newsdesk

Tue Jan 17, 2023

ChromaDex Shares Promising Findings From First-Of-Its Kind Clinical Study To Demonstrate Oral Nicotinamide Riboside Supplementation Increases Muscle Mitochondrial Biogenesis

NR improves muscle mitochondrial biogenesis, satellite cell differentiation and gut microbiota composition in first-ever five-month-long study in monozygotic twin pairs ChromaDex Corp. (NASDAQ:CDXC), a global bioscience